UNRESECTABLE THYROID GLAND CARCINOMA
Clinical trials for UNRESECTABLE THYROID GLAND CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE THYROID GLAND CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE THYROID GLAND CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets Hard-to-Treat thyroid cancer
Disease control OngoingThis early-phase study tested a combination of two targeted drugs, dabrafenib and lapatinib, in 23 people with advanced thyroid cancer that has a specific BRAF gene mutation and has stopped responding to standard treatments. The main goal was to find the safest dose of lapatinib …
Matched conditions: UNRESECTABLE THYROID GLAND CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 09:18 UTC
-
New combo therapy targets deadly thyroid cancer
Disease control OngoingThis study tests whether two drugs, lenvatinib and pembrolizumab, work together to control advanced anaplastic thyroid cancer that cannot be removed by surgery or has spread. About 25 adults with stage IVB or IVC disease will receive the combination. The goal is to see if it impr…
Matched conditions: UNRESECTABLE THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Promising combo therapy targets deadly thyroid cancer
Disease control OngoingThis study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy can help people with aggressive thyroid cancers (anaplastic or poorly differentiated) live longer. About 50 adults with advanced or inoperable cancer will receive different drug combinati…
Matched conditions: UNRESECTABLE THYROID GLAND CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:52 UTC